-+ 0.00%
-+ 0.00%
-+ 0.00%

Mersana Therapeutics Q3 2024 GAAP EPS $(0.09) Beats $(0.18) Estimate, Sales $12.598M Beat $7.530M Estimate. Cash And Equivalents Of $155.2M

Benzinga·11/13/2024 12:08:54
Listen to the news
Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.18) by 50 percent. This is a 74.29 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $12.598 million which beat the analyst consensus estimate of $7.530 million by 67.30 percent. This is a 63.65 percent increase over sales of $7.698 million the same period last year.